6.4 Million Patients Can’t Be Wrong — But Can Regulators Read What This Validation Is Actually Saying?
A Nature Medicine validation of PREVENT and SCORE2 across 6.4M individuals offers a blueprint for RWE methodology that FDA...
Semaglutide Just Passed Its Hardest Test Yet — And the FDA Has No Roadmap for What Comes Next
A landmark Lancet RCT shows once-weekly semaglutide cut heavy drinking days in 108 AUD-plus-obesity patients. The FDA approval path...
The 35% Problem: Why Isolate-Based AST Is Systematically Under-Detecting Resistance in Complicated Urinary Tract Infection
The 35% Problem — The Clinical Trial Vanguard The clinician prescribed empirically. The lab report said susceptible. Three weeks...
The Trial That Should Rewrite the Rare Disease Playbook — But Probably Won’t
AstraZeneca's Phase 3 benralizumab trial in hypereosinophilic syndrome just delivered one of the cleanest efficacy signals in rare disease...